Syros Pharmaceuticals, Inc.

Good morning and welcome to Cirrus Pharmaceuticals' second quarter 2022 financial results conference call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investor Relations and Media section of Cirrus' website at www.cirrus.com. Please be advised that today's call is being recorded. At this time, I would like to turn the call over to Courtney Solberg, Manager of Corporate Communications and Investor Relations at Cirrus.

Thank you. This morning we issued a press release announcing our second quarter 2022 financial results and a broader business update. The release is available in the Investors and Media section of Cirrus' website at www.cirrus.com. We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer, Dr. David Roth, our Chief Medical Officer, and Jason Haas, our Chief Financial Officer. We will then open the call for questions. Kristen Stevens, our Chief Development Officer, Dr. Eric Olson, our Chief Scientific Officer, and Conley Chee, our Chief Commercial Officer, are also on the call and will be available for Q&A. Before we begin, I would like to remind everyone that statements we make on this conference call will include forward-looking statements, including statements related to our planned strategic merger with Time Technologies and concurrent private placement. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factor section of our annual report on Form 10-K and our quarterly report on Form 10-Q that we filed this morning, and any other filings that we may make with the SEC in the future. In particular, the extent to which the COVID-19 pandemic continues to impact our operations and those of the third parties on which we rely will depend on future developments, which are highly uncertain and cannot be predicted with confidence. Any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. I would now like to turn the call over to Nancy.

Thank you, Courtney. Good morning, everyone, and thank you for joining us today. In the past months, we've made important progress towards building Cirrus into a late-stage company with a portfolio of small molecule medicines that have the potential to deliver new standards of care for patients with cancer. Cirrus enters the second half of this year in a position of strength. Our clinical programs are progressing well, and we are on track to have multiple data readouts over the next 18 months. This includes pivotal data from our select MBS1 trial, and data from the safety leading portions of the select AML1 phase two trial, and the phase one trial of SY5609 in pancreatic cancer. Today, we are pleased to report promising preliminary data from our dose confirmation study of SY-2101, which supports advancement of 2101 toward our Phase III trial, which is expected to initiate in the second half of 2023. Additionally, as we announced in July, we expect to secure approximately $190 million through a merger with Time Technologies and a concurrent pipe investment, both of which are expected to close in the second half of 2022. Together, along with the previously announced amendment to our loan agreement with Oxford, we anticipate these transactions will extend our cash runway into 2025, at least one year beyond the expected pivotal data from our ongoing select MDS1 phase three trial. We are incredibly grateful to our new and existing investors for their support, as well as to the time team for their collaboration throughout the strategic process. We look forward to maximizing value for patients, our combined company, and our shareholders in the months and years ahead. I will now turn the call over to David, who will review the recent progress we have made across our clinical and preclinical programs.